Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

CD3 bispecific therapies retargeting T cells to tumors have recently demonstrated striking activity in patients. Several CD3 bispecific antibodies directed against various tumor targets are currently being investigated in the clinic across different tumors. One limitation of these therapies is the r...

Full description

Bibliographic Details
Main Authors: Ulrich Wuellner, Kristina Klupsch, Fabian Buller, Isabella Attinger-Toller, Roger Santimaria, Irene Zbinden, Patricia Henne, Dragan Grabulovski, Julian Bertschinger, Simon Brack
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Antibodies
Subjects:
FynomAb
Fynomer
bispecific antibody
T cell retargeting
oncology
CD3
HER2
selectivity
toxicity
Online Access:http://www.mdpi.com/2073-4468/4/4/426

Similar Items

Similar Items